FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2888943877> ?p ?o ?g. }

• W2888943877 endingPage "1501.e11" @default.
• W2888943877 startingPage "1493" @default.
• W2888943877 abstract "•High-throughput enzyme-linked immunoassays were developed to measure lipoprotein-associated apolipoprotein C-III (apoC-III) levels. •apoCIII-apoB, apoCIII-Lp(a), and apoCIII-apoAI were measured in EPIC-Norfolk. •apoCIII-apoB, apoCIII-Lp(a), and apoCIII-apoAI reflect atherogenic lipid particles. •apoCIII-apoB, apoCIII-Lp(a), and apoCIII-apoAI do not independently predict risk of coronary artery disease events. •Their role in patients with prior history of coronary artery disease needs to be evaluated. Background Plasma apolipoprotein C-III (apoC-III) levels are associated with coronary artery disease (CAD) risk. Objective To assess whether lipoprotein-associated apoC-III levels predict risk of CAD events. Methods apoC-III associated with apoB, apoAI, and Lp(a) (apoCIII-apoB, apoCIII-apoAI, and apoCIII-Lp(a), respectively) were measured using high-throughput chemiluminescent enzyme-linked immunoassays in 2711 subjects (1879 controls and 832 cases with CAD) in the European Prospective Investigation into Cancer and Nutrition-Norfolk prospective population study with 7.4 years of follow-up. These measures were correlated with a variety of lipid measurements and the presence of CAD. The indices of “total apoCIII-apoB” and “total apoCIII-apoAI” were derived by multiplying plasma apoB and apoAI, respectively. Results apoCIII-apoB (P = .001), apoCIII-Lp(a) (P < .001), apoCIII-apoAI (P = .005) were higher in cases vs controls; tended to correlate positively with body mass index, hsCRP, apoC-III, low-density lipoprotein (LDL) cholesterol, triglycerides, remnant cholesterol, very low density lipoprotein, LDL and high-density lipoprotein particle number and very low density lipoprotein size; but negatively with LDL and high-density lipoprotein particle size (P < .001 for all). apoCIII-apoB, apoCIII-apoAI, apoCIII-Lp(a), total apoCIII-Lp(a), and total apoCIII-apoB were predictors of CAD after adjustment of age, sex, body mass index, smoking, diabetes, hypertensive and lipid-lowering drug use, but they lost their significance after further adjustment of lipid and lipoprotein variables. Conclusions This study suggests that enzyme-linked immunoassay–measured lipoprotein-associated apoC-III markers reflect atherogenic lipid particles but do not independently predict risk of CAD events. Plasma apolipoprotein C-III (apoC-III) levels are associated with coronary artery disease (CAD) risk. To assess whether lipoprotein-associated apoC-III levels predict risk of CAD events. apoC-III associated with apoB, apoAI, and Lp(a) (apoCIII-apoB, apoCIII-apoAI, and apoCIII-Lp(a), respectively) were measured using high-throughput chemiluminescent enzyme-linked immunoassays in 2711 subjects (1879 controls and 832 cases with CAD) in the European Prospective Investigation into Cancer and Nutrition-Norfolk prospective population study with 7.4 years of follow-up. These measures were correlated with a variety of lipid measurements and the presence of CAD. The indices of “total apoCIII-apoB” and “total apoCIII-apoAI” were derived by multiplying plasma apoB and apoAI, respectively. apoCIII-apoB (P = .001), apoCIII-Lp(a) (P < .001), apoCIII-apoAI (P = .005) were higher in cases vs controls; tended to correlate positively with body mass index, hsCRP, apoC-III, low-density lipoprotein (LDL) cholesterol, triglycerides, remnant cholesterol, very low density lipoprotein, LDL and high-density lipoprotein particle number and very low density lipoprotein size; but negatively with LDL and high-density lipoprotein particle size (P < .001 for all). apoCIII-apoB, apoCIII-apoAI, apoCIII-Lp(a), total apoCIII-Lp(a), and total apoCIII-apoB were predictors of CAD after adjustment of age, sex, body mass index, smoking, diabetes, hypertensive and lipid-lowering drug use, but they lost their significance after further adjustment of lipid and lipoprotein variables. This study suggests that enzyme-linked immunoassay–measured lipoprotein-associated apoC-III markers reflect atherogenic lipid particles but do not independently predict risk of CAD events." @default.
• W2888943877 created "2018-09-07" @default.
• W2888943877 creator A5002212896 @default.
• W2888943877 creator A5004099465 @default.
• W2888943877 creator A5037079092 @default.
• W2888943877 creator A5040307802 @default.
• W2888943877 creator A5057904076 @default.
• W2888943877 creator A5068573572 @default.
• W2888943877 creator A5077286184 @default.
• W2888943877 creator A5077848934 @default.
• W2888943877 creator A5081557648 @default.
• W2888943877 creator A5090498118 @default.
• W2888943877 creator A5091030211 @default.
• W2888943877 date "2018-11-01" @default.
• W2888943877 modified "2023-10-16" @default.
• W2888943877 title "Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study" @default.
• W2888943877 cites W1925850247 @default.
• W2888943877 cites W1984875752 @default.
• W2888943877 cites W2032456325 @default.
• W2888943877 cites W2052644460 @default.
• W2888943877 cites W2057271976 @default.
• W2888943877 cites W2134450273 @default.
• W2888943877 cites W2138061818 @default.
• W2888943877 cites W2145813488 @default.
• W2888943877 cites W2163969089 @default.
• W2888943877 cites W2168095967 @default.
• W2888943877 cites W2168420374 @default.
• W2888943877 cites W2170009139 @default.
• W2888943877 cites W2170221839 @default.
• W2888943877 cites W2216998043 @default.
• W2888943877 cites W2275234007 @default.
• W2888943877 cites W2315899065 @default.
• W2888943877 cites W2318839442 @default.
• W2888943877 cites W2471143596 @default.
• W2888943877 cites W2588878434 @default.
• W2888943877 cites W2596179513 @default.
• W2888943877 cites W2735307121 @default.
• W2888943877 cites W2747264648 @default.
• W2888943877 cites W2770370411 @default.
• W2888943877 doi "https://doi.org/10.1016/j.jacl.2018.08.010" @default.
• W2888943877 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6970616" @default.
• W2888943877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30249512" @default.
• W2888943877 hasPublicationYear "2018" @default.
• W2888943877 type Work @default.
• W2888943877 sameAs 2888943877 @default.
• W2888943877 citedByCount "7" @default.
• W2888943877 countsByYear W28889438772020 @default.
• W2888943877 countsByYear W28889438772021 @default.
• W2888943877 countsByYear W28889438772023 @default.
• W2888943877 crossrefType "journal-article" @default.
• W2888943877 hasAuthorship W2888943877A5002212896 @default.
• W2888943877 hasAuthorship W2888943877A5004099465 @default.
• W2888943877 hasAuthorship W2888943877A5037079092 @default.
• W2888943877 hasAuthorship W2888943877A5040307802 @default.
• W2888943877 hasAuthorship W2888943877A5057904076 @default.
• W2888943877 hasAuthorship W2888943877A5068573572 @default.
• W2888943877 hasAuthorship W2888943877A5077286184 @default.
• W2888943877 hasAuthorship W2888943877A5077848934 @default.
• W2888943877 hasAuthorship W2888943877A5081557648 @default.
• W2888943877 hasAuthorship W2888943877A5090498118 @default.
• W2888943877 hasAuthorship W2888943877A5091030211 @default.
• W2888943877 hasBestOaLocation W28889438772 @default.
• W2888943877 hasConcept C126322002 @default.
• W2888943877 hasConcept C134018914 @default.
• W2888943877 hasConcept C2778163477 @default.
• W2888943877 hasConcept C2778213512 @default.
• W2888943877 hasConcept C2780072125 @default.
• W2888943877 hasConcept C2780221984 @default.
• W2888943877 hasConcept C2908647359 @default.
• W2888943877 hasConcept C62746215 @default.
• W2888943877 hasConcept C71924100 @default.
• W2888943877 hasConcept C99454951 @default.
• W2888943877 hasConceptScore W2888943877C126322002 @default.
• W2888943877 hasConceptScore W2888943877C134018914 @default.
• W2888943877 hasConceptScore W2888943877C2778163477 @default.
• W2888943877 hasConceptScore W2888943877C2778213512 @default.
• W2888943877 hasConceptScore W2888943877C2780072125 @default.
• W2888943877 hasConceptScore W2888943877C2780221984 @default.
• W2888943877 hasConceptScore W2888943877C2908647359 @default.
• W2888943877 hasConceptScore W2888943877C62746215 @default.
• W2888943877 hasConceptScore W2888943877C71924100 @default.
• W2888943877 hasConceptScore W2888943877C99454951 @default.
• W2888943877 hasFunder F4320319985 @default.
• W2888943877 hasFunder F4320321642 @default.
• W2888943877 hasFunder F4320321800 @default.
• W2888943877 hasFunder F4320332161 @default.
• W2888943877 hasFunder F4320334626 @default.
• W2888943877 hasIssue "6" @default.
• W2888943877 hasLocation W28889438771 @default.
• W2888943877 hasLocation W28889438772 @default.
• W2888943877 hasLocation W28889438773 @default.
• W2888943877 hasLocation W28889438774 @default.
• W2888943877 hasLocation W28889438775 @default.
• W2888943877 hasOpenAccess W2888943877 @default.
• W2888943877 hasPrimaryLocation W28889438771 @default.
• W2888943877 hasRelatedWork W1966967166 @default.
• W2888943877 hasRelatedWork W1981345773 @default.
• W2888943877 hasRelatedWork W1999568358 @default.

• next